Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzalutamide in Localized Prostate Cancer (ENACT)
NCT02799745Phase 2Completed
- Sponsor
- Astellas Pharma
- Start
- Jun 2016
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of enzalutamide in prostate cancer (PCa), sponsored by Astellas Pharma. Started Jun 2016; status: completed.
02
Drugs
enzalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02799745.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02799745.